Compare BLNK & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | PMVP |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.9M | 73.1M |
| IPO Year | 2008 | 2020 |
| Metric | BLNK | PMVP |
|---|---|---|
| Price | $0.83 | $1.50 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.95 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 447.8K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $126,197,000.00 | N/A |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $19.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.83 |
| 52 Week High | $2.65 | $1.88 |
| Indicator | BLNK | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 68.40 | 59.40 |
| Support Level | $0.63 | $1.37 |
| Resistance Level | $0.97 | $1.53 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 91.91 | 89.30 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.